Get the Stockscreener App
0.9911
0.52%
-0.0052
Pre-market:
.98
-0.0111
-1.12%
Revelation Biosciences Inc stock is traded at $0.9911, with a volume of 89,355.
It is down -0.52% in the last 24 hours and up +1.20% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
See More
Previous Close:
$0.9963
Open:
$1.02
24h Volume:
89,355
Relative Volume:
1.33
Market Cap:
$3.87M
Revenue:
-
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.0251
EPS:
-39.4678
Net Cash Flow:
$-8.76M
1W Performance:
-1.87%
1M Performance:
+1.20%
6M Performance:
-74.19%
1Y Performance:
-68.79%
1-Day Range:
$0.9889
$1.06
1-Week Range:
$0.9889
$1.06
52-Week Range:
$0.875
$12.88
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.9911 | 3.87M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Revelation Biosciences Inc Stock (REVB) Latest News
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate
Revelation Biosciences expands AKI advisory board - Investing.com UK
Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView
Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan
Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa
Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Rutland Herald
REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com
Revelation Biosciences (REVB) Shows Minimal Movement as Shares Trade Near Key SupportTime Weighted Price - newsline.com
REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com
Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate
REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate
REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate
Revelation Biosciences Inc. (REVB) Edges Lower, Maintains Support Near $1.01Exhaustion Gap - The Legal Advocate
REVB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesEarnings Outlook Update - newsline.com
Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedWave Extension - The Legal Advocate
Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser
Revelation Biosciences Inc. (REVB) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentEarnings Yield Spread - Newser
Revelation Biosciences (REVB) Consolidates Near Key Support at $1.03Institutional Grade Picks - Newser
REVB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Awaits Clinical MilestonesEPS Surprise History - The Legal Advocate
Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet - Bez Kabli
Revelation Biosciences (REVB) Stock Forum and Discussion - Moomoo
Revelation Biosciences (REVB) Climbs +4.51% — Resistance at $1.07 in Focus 2026-05-18Community Risk Signals - Newser
Revelation Biosciences, Inc.Common Stock (NQ: REVB - The Chronicle-Journal
Armistice Capital reports 323,241 REVB shares (REVB) — 7.80% stake disclosed - Stock Titan
Revelation Biosciences announces pricing of $4M public offering - MSN
TradingKey - TradingKey
REVB Stock Price, Quote & Chart | REVELATION BIOSCIENCES INC (NASDAQ:REVB) - ChartMill
Revelation Biosciences (NASDAQ: REVB) seeks wide reverse split authority in 2026 proxy - Stock Titan
Revelation Biosciences releases proxy materials with CEO update - Investing.com
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders - The Joplin Globe
How one 300-patient trial could unlock a new acute kidney injury treatment - Stock Titan
The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08Verified Stock Signals - Newser
EX-99.1 - SEC.gov
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 - Times Argus
Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed - Stock Titan
FDA agrees to single Gemini study for acute kidney injury - Stock Titan
BRIEF-Revelation Biosciences Inc Q1 EPS USD -2.71 - TradingView
Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge - Stock Titan
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):